Cited by 369SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Researchvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Open access

Seydoux, Emilie, Homad, Leah J., MacCamy, Anna J., Parks, K. Rachael, Hurlburt, Nicholas K., Jennewein, Madeleine F., Akins, Nicholas R., Stuart, Andrew B., Wan, Yu-Hsin, Feng, Junli, Whaley, Rachael E., Singh, Suruchi, Boeckh, Michael, Cohen, Kristen W., McElrath, M. Juliana, Englund, Janet A., Chu, Helen Y., Pancera, Marie, McGuire, Andrew T., Stamatatos, Leonidas·2020·Immunity

DOI 10.1016/j.immuni.2020.06.001PMC PMC7276322

Open this paper in CoChat — free account Open PDF

Abstract

Antibody responses develop following SARS-CoV-2 infection, but little is known about their epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We isolated B cells specific for the SARS-CoV-2 envelope glycoprotein spike (S) from a COVID-19-infected subject 21 days after the onset of clinical disease. 45 S-specific monoclonal antibodies were generated. They had undergone minimal somatic mutation with limited clonal expansion, and three bound the receptor-binding domain (RBD). Two antibodies neutralized SARS-CoV-2. The most potent antibody bound the RBD and prevented binding to the ACE2 receptor, while the other bound outside the RBD. Thus, most anti-S antibodies that were generated in this patient during the first weeks of COVID-19 infection were non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 S-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive and/or therapeutic potential and can serve as templates for vaccine design.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2020.06.001

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048 · cited 1×
“5 million documented cases of COVID-19 and over 420,000 deaths (Dong et al., 2020).”
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · cited 10×
“, 2020), and immunization with SARS S protein can elicit anti-SARS-CoV-2 neutralizing antibodies in wild-type and humanized mice, as well as llamas (Walls et al., 2020; Wang et al., 2020;Wrapp et al., 2020).”
BackgroundMethodResultInfluential
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Self-citation
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · cited 1×
“Like SARS-CoV, SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry receptor binding with nM affinity (Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Hoffmann et al., 2020; Letko et al., 2020; Ou et al., 2020).”
Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341 · cited 4×
“Although SARSCoV and SARS-CoV-2 share extensive amino acid sequence in the RBD (74%), and both viruses utilize human ACE2 for entry, the amino acid identity in the receptor binding motif is only 50% (Wan et al., 2020).”
InfluentialSelf-citation
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109 · cited 1×
“Like SARS-CoV, SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry receptor binding with nM affinity (Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Hoffmann et al., 2020; Letko et al., 2020; Ou et al., 2020).”
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097 · cited 2×
“Like SARS-CoV, SARS-CoV-2 utilizes angiotensin-converting enzyme 2 (ACE2) as an entry receptor binding with nM affinity (Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Hoffmann et al., 2020; Letko et al., 2020; Ou et al., 2020).”
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614 · cited 3×
“Although binding and neutralizing antibody responses are known to develop following SARS-CoV-2 infection (Ni et al., 2020; Okba et al., 2020), no information is currently available on the epitope specificities, clonality, binding affinities, and neutralizing potentials of the antibody response.”
BackgroundResultInfluential

Flagged first, then by citations

Show all 44 references

1 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–369 of 369

Heterologous booster immunization with SARS-CoV-2 spike protein after mRNA vaccine elicits durable and broad antibody responsesPreprint
Takano, T., Sato, T., Kotaki, R., Moriyama, S., Shinoda, M., Kabasawa, K., Shimada, N., Kousaka, M., Adachi, Y., Onodera, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2014078/v1 · Cited by 4
Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein
Ert, H. A. V., Bohan, D., Rogers, K. J., Fili, M., Chávez, R. A. R., Qing, E., Han, C., Dempewolf, S., Hu, G., Schwery, N., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02676-21 · Cited by 3
“A large proportion of spike-targeting antibodies elicited by infection are non-neutralizing 273 (36, 37).”
Background
Regulatory cytokines modulate early isotype-specific response associated with COVID-19 survival
Castro-Trujillo, S., Castro-Meneses, J., Rojas, M. C., Castro-Amaya, M., Lastra, G., & Narváez, C. F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543626 · Cited by 3
“Given that somatic hypermutation is not essential for the development of neutralizing antibodies against SARS-CoV-2 (36), the most likely protective mechanism behind these ﬁ ndings is the neutralizing capacity of these early IgG-S and RBD antibodies, as their levels are a strong correlate of…”
The impact of high-resolution structural data on stemming the COVID-19 pandemic
Cox, R. M., & Plemper, R. K. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.05.005 · Cited by 3
Drivers of medical spending behaviour amid the COVID-19 pandemic: Heuristic or systematic
Phan, T. N. T., Ngo, V. M., & Nguyen, H. H. (2022) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2022.100116 · Cited by 3
Antibody Response and Therapy in COVID-19 Patients: Significance in Vaccine DevelopmentPreprint
Lu, L., Zhang, H., Zhan, M., Jiang, J., Yin, H., Dauphars, D. J., Li, S., Li, Y., & He, Y.-W. (2020) · Preprints.org · doi:10.20944/preprints202008.0166.v1 · Cited by 3
“lymphocytes and cloning of paired heavy and light chains of anti-SARS-CoV-2 specific immunoglobulin (Brouwer et al., 2020;Chi et al., 2020;Hansen et al., 2020;Ju et al., 2020;Robbiani et al., 2020;Rogers et al., 2020;Seydoux et al., 2020;Shi et al., 2020;Wan et al., 2020a;Wu et al., 2020c;Zost et al., 2020)(Table 2).”
BackgroundInfluential
Development of an Optical Assay to Detect SARS-CoV-2 Spike Protein Binding Interactions with ACE2 and Disruption of these Interactions Using Electric CurrentPreprint
Ahmad, M. A., Mustafa, F., Panicker, N. G., & Rizvi, T. A. (2020) · medRxiv · doi:10.1101/2020.11.24.20237628 · Cited by 4
Beginnings of coinhibition
Sinclair, N. R. S. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13098 · Cited by 2
Natural immune response and protection from SARS-CoV-2 reinfection
Margiotti, K., Fabiani, M., Mesoraca, A., & Giorlandino, C. (2021) · Acta Virologica · doi:10.4149/av_2021_401 · Cited by 2
Analysis of Clinical Course and Vaccination Influence on Serological Response in COVID-19 Convalescents
Adamczuk, J., Czupryna, P., Dunaj, J., Kruszewska, E., Pancewicz, S. A., Kamiński, K. A., Borawski, K., Grygorczuk, S., & Moniuszko-Malinowska, A. M. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02485-21 · Cited by 2
“could neutralize viral infectivity (4, 5).”
High seroprevalence against SARS-CoV-2 in non-vaccinated patients with inflammatory bowel disease from Northern India
Kante, B., Vuyyuru, S. K., Gupta, R., Dwivedi, T., Kumar, P., Mundhra, S. K., Golla, R., Virmani, S., Verma, M., Makharia, G. K., et al. (2023) · Indian Journal of Gastroenterology · doi:10.1007/s12664-022-01310-y · Cited by 2
Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants
Oladunni, F. S., Park, J., Chiem, K., Ye, C., Piepenbrink, M. S., Walter, M. R., Kobie, J. J., & Martínez‐Sobrido, L. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114084 · Cited by 2
The quest continues for perfect COVID-19 vaccine
Bhatia, R. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_4165_20 · Cited by 2
Insights into biological therapeutic strategies for COVID-19
Tian, X., Li, C., Wu, Y., & Ying, T. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.02.001 · Cited by 2
Differential Antibody Response to SARS-CoV-2 Antigens in Recovered and Deceased Iranian COVID-19 Patients
Maghsood, F., Hassani, D., Salimi, V., Kardar, G., Khoshnoodi, J., Ghaderi, A., Raeeskarami, S. R., Rostamian, A., Seyyedsalehi, M. S., Fesharaki, R. A., et al. (2021) · Viral immunology · doi:10.1089/vim.2021.0061 · Cited by 2
“Taking into consideration the fact that RBD, but not N, antibodies are potentially neutralizing and have been re-ported to closely correlate with viral neutralization (22,32,34,36), this would raise questions about the functional signiﬁcance of these antibodies in deceased patients.”
The quantitative landscape of the neutralizing antibody response to SARS-CoV-2Preprint
Padmanabhan, P., Desikan, R., & Dixit, N. M. (2020) · medRxiv · doi:10.1101/2020.09.25.20201996 · Cited by 2
Neutralizing antibody responses 10 months after mild and moderately-severe SARS-CoV-2 infectionPreprint
Dehgani‐Mobaraki, P., Zaidi, A. K., Porreca, A., Floridi, A., & Floridi, E. (2021) · medRxiv · doi:10.1101/2021.02.22.21252225 · Cited by 2
Monoclonal Antibody Therapeutics for Infectious Diseases: Beyond Normal Human ImmunoglobulinPreprint
Otsubo, R., & Yasui, T. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4022365 · Cited by 2
Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concernPreprint
Rubio, A. A., Baharani, V. A., Dadonaite, B., Parada, M., Abernathy, M. E., Wang, Z., Lee, Y. E., Eso, M. R., Phung, J. L., Ramos, I., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.05.592584 · Cited by 2
Human IGH germline gene diversity and allele frequencies in 2486 individuals from 25 global populations delineated by ultra-high throughput genotypingPreprint
Corcoran, M., Narang, S., Kaduk, M., Chernyshev, M., Färnert, A., Sundling, C., & Hedestam, G. B. K. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.06.668935 · Cited by 2
Progress and prospect of SARS-CoV-2 NTD-specific antibodies
Qi, G. U. I., Zhang, Z., & Ju, B. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0175 · Cited by 1
No evidence of direct activation of human neutrophil responses by multivalent prefusion trimeric SARS-CoV-2 Spike protein ex vivo
Fortin, A., Huot, S., Caron, E., Laflamme, C., Pagliuzza, A., Chomont, N., Gilbert, C., Zhang, B., Kwong, P. D., Pouliot, M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0332261 · Cited by 1
“This antibody, derived from B cells specific for the SARS-CoV-2 S glycoprotein, was isolated from a COVID-19-infected individual and targets the receptor-binding domain (RBD; residues 319–591), effectively blocking the RBD-ACE2 interaction [57].”
Cell-free immuno-profiling on a genetically programmed biochip
Dupin, A., Vonshak, O., Nir, V., Levanon, M., Avidan, N., Divon, Y., Peleg, S., Thompson, S., Noireaux, V., Daube, S. S., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02058-0 · Cited by 1
“Bars 10 and 11). c , RBD2 primary sequence with amino acids that were identified to interact (filled circle) or not interact (empty circles) with anti-RBD2 monoclonal antibodies 5G8, CV30, CA11 and HL1003.”
Influential
A Bioinspired Hemostatic Nano-Sponge: Sustained Release of Honeysuckle from Mesoporous Silica for Integrated Bleeding Control and Wound Repair
Mo, Z., Zhang, Y., Xiao, X., Zhong, Y., Yang, J., Huang, M., Zhang, L., & Tang, Y. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01829 · Cited by 1
Immune-focused RBD nanoparticles induce cross-reactive, RBS-directed responses capable of variant-resistant SARS-CoV-2 neutralization
Konrath, K. M., Liaw, K., Tursi, N. J., McCanna, M. E., Warner, B. M., Gary, E. N., Zhu, X., Livingston, C., Monastra, C., Frase, D. M., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1013905 · Cited by 1
Chronic infection perturbs the affinity hierarchy of antiviral B cells
Dimitrova, M., Abreu-Mota, T., Fixemer, J., Bonilla, W. V., Marx, A., Lu, M., Tintignac, K., Kastner, A. L., Ertuna, Y. I., Florova, M., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2532422123 · Cited by 1
Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS‐CoV‐2 Omicron Variants
Lv, H., Feng, Z., Teo, Q. W., Chen, C., Gopal, A. B., Choi, D., Tan, T. J. C., Tang, Y. S., Siu, L. Y.-L., Nourmohammad, A., et al. (2026) · Advanced Science · doi:10.1002/advs.76522 · Cited by 2
Risk of SARS-CoV-2 transmission in the close contacts in a small rural area in the Veneto Region (NE-Italy): past evidence for future scenarios
Bassanello, M., Geppini, R., Bonsembiante, E., Coli, U., Farencena, A., D'Aquino, M., Gambaro, A., Buja, A., & Baldovin, T. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1223109 · Cited by 1
Distinct immune responses in people living with HIV following SARS-CoV-2 recovery
Mielke, D., Li, S. S., Schuster, D. J., Li, X., Hu, J., Karuna, S., Seaton, K. E., Brackett, C., Dunn, B., Keyes, T., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00839-1 · Cited by 2
“Cryopreserved PBMCs from SARS-CoV-2-convalescent participants and a pre-pandemic SARS-CoV-2-naive donor were thawed at 37 °C and stained for SARS-CoV-2-speci ﬁ c memory B cells as described previously 27 with a panel of ﬂ uor-escently labeled antibodies (Supplementary Table 12).”
Self-citation
Rekonvaleszentenplasma zur Behandlung von schwerem COVID-19: Rationale und Design einer randomisierten, offenen klinischen Studie von Rekonvaleszentenplasma verglichen mit bestmöglicher supportiver Behandlung (CAPSID-Studie)
Körper, S., Jahrsdörfer, B., Appl, T., Klüter, H., Seifried, E., & Schrezenmeier, H. (2020) · Transfusionsmedizin · doi:10.1055/a-1090-0408 · Cited by 1
“Seydoux et al. analysierten die Spezifität der Antikörper bei einem Patienten 21 Tage nach Symptombeginn [30]: Antikörper gegen die Rezeptor-bindende Domäne (RBD), welche die Interaktion zwischen dem S-Protein von SARS‑CoV‑2 und dem ACE2-Rezeptor hemmen, sind am stärksten neutralisierend.”
BackgroundInfluential
SARS-CoV-2 reinfection
Romera, I., Nunez, K., Calizaya, M., Baeza, I., Molina, R., & Morillas, J. (2021) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2021.04.009 · Cited by 1
Reinfección por SARS-CoV-2
Romera, I., Nunez, K., Calizaya, M., Baeza, I., Molina, R., & Morillas, J. (2021) · Medicina Intensiva · doi:10.1016/j.medin.2021.01.007 · Cited by 1
The Trend of Neutralizing Antibody Response Against SARS-CoV-2 and the Cytokine/Chemokine Release in Patients with Differing Severities of COVID-19: All Individuals Infected with SARS-CoV-2 Obtained Neutralizing AntibodyPreprint
Tjan, L. H., Nagano, T., Furukawa, K., Nishimura, M., Arii, J., Fujinaka, S., Iwata, S., Nishimura, Y., & Mori, Y. (2020) · medRxiv · doi:10.1101/2020.08.05.20168682 · Cited by 1
“12 young man with a mild SARS-CoV-2 infection in whom neutralizing antibody titer rapidly 241 increased from day 4 until day 20 [18].”
Background
Application of a Method for Engineering Multivalent Antibodies to Substantially Enhance Functional affinity of Clinical Trial Anti-SARS-CoV-2 AntibodiesPreprint
Leach, A., Miller, A., Bentley, E., Mattiuzzo, G., Thomas, J. C., McAndrew, C., van Montfort, R., & Rabbitts, T. (2021) · Research Square · doi:10.21203/rs.3.rs-259484/v1 · Cited by 1
The Efficacy of Casirivimab/Imdevimab in Solid Organ Transplant Recipients with Mild-To-Moderate COVID-19Preprint
Tagaya, E., Kikuchi, K., Mitsuda, T., Ebihara, F., Maruyama, T., Hamada, Y., Kimura, T., Unagami, K., Kanzawa, T., Sekiguchi, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1361782/v1 · Cited by 1
The diversity of the glycan shield of sarbecoviruses closely related to SARS-CoV-2Preprint
Allen, J., Ivory, D., Song, S. G., He, W.-T., Capozzola, T., Yong, P., Burton, D., Andrabi, R., & Crispin, M. (2022) · bioRxiv · doi:10.1101/2022.08.24.505118 · Cited by 2
“…domain (RBD) and is poorly shielded by N-linked glycans (Barnes et al., 2020; Cao et al., 2020; Chi et al., 2020; He et al., 2022; Ju et al., 2020; Pinto et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; Seydoux et al., 2020; Shi et al., 2020; Wu et al., 2020; Yuan et al., 2020, 2022).”
Dissecting the impact of somatic hypermutation on SARS-CoV-2 neutralization and viral escapePreprint
Korenkov, M., Zehner, M., Cohen-Dvashi, H., Borenstein-Katz, A., Kottege, L., Janicki, H., Vanshylla, K., Weber, T., Gruell, H., Koch, M., et al. (2023) · bioRxiv · doi:10.1101/2023.05.09.539943 · Cited by 1
Chronic Infection Perturbs the Affinity Hierarchy of Antiviral B CellsPreprint
Dimitrova, M., Abreu-Mota, T., Fixemer, J., Bonilla, W. V., Marx, A., Lu, M., Tintignac, K., Kastner, A. L., Ertuna, Y. I., Florova, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.21.671513 · Cited by 1
Laboratory diagnostics of COVID-19
Lochman, I., Kratochvíla, J., & Friedecky, B. (2020) · Klinická biochemie a metabolismus · doi:10.61568/kbm.2020.018
AR222, AR249, AS274, AS702 and AS708 antibodies recognize the spike S protein from SARS-CoV-2 by immunofluorescence
Marchetti, A., & Zenhausern, F. (2020) · Antibody Reports · doi:10.24450/journals/abrep.2020.e228
“Geneva University Library Open Access Publications https://oap.unige.ch/journals/abrep | ISSN 2624-8557 ABCD Clone Epitope Reference Yield (mg/L) AQ806 VHH-72 S1/RBD Wrapp et al., 2020 50 AR222 Sb#14 S1/RBD Walter et al., 2020 60 AR249 Sb#45 S1/RBD Walter et al., 2020 100 AS274 H4 S1/RBD Wu et al., 2020 20 AS702 CV24…”
AI334, AQ806, AR222, AR249, AS274, AS708, RB572, RB574 and RB596 antibodies recognize SARS-CoV-2 viral particles by dot blot
Lacombe, J., Zenhausern, F., & Cosson, P. (2020) · Antibody Reports · doi:10.24450/journals/abrep.2020.e273
“…2006 50 AQ806 VHH-72 S1 Wrapp et al., 2020 50 AR222 Sb#14 S1 Walter et al., 2020 60 AR249 Sb#45 S1 100 AS274 H4 S1 Wu et al., 2020 20 AS708 CV30 S1 Seydoux et al., 2020 20 RB572 MRB572 M Hammel and Zenhausern, 2020 10 RB574 MRB574 M 10 RB596 MRB596 S2 Farrera-Soler et al., 2020 100 Antigen:…”
The Frequency of SARS-CoV-2 Specific Memory B Cells in COVID-19 Recovered Patients Remain Stable While Antibodies Decay Over TimePreprint
Vaisman‐Mentesh, A., Dror, Y., Maimon, L., Kigel, A., Rosenstein, S., Eyran, T., Bahar, Y., Taussig, D. C., Tur‐Kaspa, R., Kournos, T., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3751788
Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2Preprint
Lv, H., Tsang, O., So, R. T. Y., Wang, Y.-Q., Yuan, M., Liu, H., Yip, G. K., Teo, Q., Lin, Y., Liang, W.-W., et al. (2021) · bioRxiv · doi:10.1101/2021.02.17.431722
Long-term and short-term immunity to SARS-CoV-2: why it matters
Zaunders, J., & Phetsouphanh, C. (2021) · Microbiology Australia · doi:10.1071/ma21010
Severe acute respiratory syndrome coronavirus 2 targeted antibodies cocktail and B cell receptor interplay: interventions to trigger vaccine development
Haneef, K., Saleem, R., Khan, M. S. I., Adeyinka, O. S., Banday, S., Asghar, M. U., Rahman, Z. U., & Fatima, Z. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00011
“6 RBD N/A absent [114, 115] COVA1-12 Humanized 1.”
Lower SARS-CoV-2-Specific Humoral Immunity in People Living With HIV-1 Recovered From Symptomatic Non-Hospitalized COVID-19Preprint
Schuster, D. J., Karuna, S., Brackett, C., Wesley, M. S., Li, S. S., Eisel, N., Tenney, D., Hilliard, S., Yates, N. L., Heptinstall, J., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000542
Faculty Opinions recommendation of Designed proteins assemble antibodies into modular nanocages.
Hashimoto, T. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739856245.793585845
Germinal center-derived broadly neutralizing antibodies adapt to SARS-CoV-2 antigenic driftPreprint
Shitaoka, K., Kawano, Y., Higashiura, A., Mizoguchi, Y., Hashiguchi, T., Nishimichi, N., Huang, S., Ito, A., Yamamoto, A., Ohki, S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.26.477937
AI334, AQ806, AR222, AR249, AS274, AS702, AS708, RB590, RB591 and RB596 antibodies recognize the spike S protein from SARS-CoV-2 by western blot
Marchetti, A., & Zenhausern, F. (2022) · Antibody Reports · doi:10.24450/journals/abrep.2022.e725
“…al., 2020 60 AR249 Sb#45 S1/RBD Walter et al., 2020 100 AS274 H4 S1/RBD Wu et al., 2020 20 AS702 CV24 S1 Seydoux et al., 2020 20 AS708 CV30 S1/RBD Seydoux et al., 2020 20 RB590 RB590 Cytosolic this work 50 RB591 RB591 Cytosolic this work 120 RB596 RB596 S2 Farrera-Soler et al., 2020 100 Antigen:…”
Epistasis at the SARS-CoV-2 RBD Interface and the Propitiously Boring Implications for Vaccine EscapePreprint
Rochman, N. D., Faure, G., Wolf, Y. I., Freddolino, P. L., Zhang, F., & Koonin, E. V. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3945930
Volume 42 Number 1
(2021) · Microbiology Australia · doi:10.1071/mav42n1
Redesign computacional de anticorpos específicos para o domínio de ligação ao receptor (RBD) da proteína spike de SARS-CoV-2 com afinidade de ligação aumentada às sublinhagens ômicron
Pereira, C. (2023) · doi:10.14393/ufu.di.2023.86
Protection of SARS-CoV-2 trial vaccines in human is a function of the viral genomes
Saganuwan, S. A. (2023) · RPS Pharmacy and Pharmacology Reports · doi:10.1093/rpsppr/rqad020
Using deep learning via long-short-term memory model prediction of COVID-19 situation in India
Rout, S. K., Sahu, B., Das, A. K., Mohanty, S. N., & Sharma, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19413-9.00010-2
Development of plant-produced subunit vaccine and therapeutic protein for COVID-19
Siriwattananon, K. (2021) · Chula Digiverse · doi:10.58837/chula.the.2021.306
Characterization of B‐cell receptor clonality and immunoglobulin gene usage at multiple time points during active SARS‐CoV‐2 infection
Arons, E., Henry, K. N., Haas, C. J., Gould, M., Tsintolas, J., Mauter, J. T., Zhou, H., Burbelo, P. D., Cohen, J. I., & Kreitman, R. J. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29179
“Expansion of unmutated rearrangements was reported following Rotavirus 37 and Dengue virus 38 infections, as well as in individual COVID ‐ 19 samples 14,22,24,33,34 and could be explained by expansion of B ‐ cells producing natural or polyreactive antibodies.”
BackgroundResultInfluential
Strategies to determine positive anti-SARS-CoV-2 memory T lymphocyte response during the evolution of an epidemic
Nel, I., Ithayakumar, A., Blumenthal, N., Duneton, C., Guérin, V., Viala, J., Dollfus, C., Baudouin, V., Guilmin‐Crépon, S., Theodorou, I. D., et al. (2024) · Journal of Immunological Methods · doi:10.1016/j.jim.2024.113712
Immunoglobulin Clonotype and Ontogeny Inference
Polak, P., Mehr, R., & Yaari, G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95502-7.00058-0
Response of Recombinant Protein Based on Epitopes of the Spike Protein SARS-CoV-2 Indonesian Isolate: Immune and Leucocytes
Narulita, E., Febrianti, R. A., Sulistyaningsih, E., Ludfi, A. S., Meirina, Y. P., Priyanto, J. A., Priyambodo, P., & Kurniawan, A. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00185
“SARS COV-2/COVID-19 Pandemic”. First is do no harm (Primum non nocere), the evolution of therapy and treatment COVID-19, a literature review
E., M., MD, G. M. G., MD, F. G. J., Hernández Silva, S. M. D., Robles Díaz, M. T. N. J., Soto Acosta, C. Y., & Landa Chávez, T. L. (2025) · Journal of Anesthesia & Critical Care Open Access · doi:10.15406/jaccoa.2025.17.00620
Epitope-driven polyfunctional divergence of SARS-CoV-2 RBD antibodies
Rosenbaum, P., Planchais, C., Bruel, T., Beretta, M., Staropoli, I., Bolland, W., Guivel‐Benhassine, F., Planas, D., French COVID Cohort Study Group, CORSER Study Group, et al. (2026) · iScience · doi:10.1016/j.isci.2026.117345
Additional file 1 of Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
Valdez‐Cruz, N. A., García-Hernández, E., Espitia, C., Cobos-Marín, L., Altamirano, C., Bando-Campos, C. G., Cofas‐Vargas, L. F., Coronado-Aceves, E. W., González-Hernández, R. A., Hernández‐Peralta, P., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14471586
Additional file 1 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Chiang, H.-L., Liang, K.-H., Lu, R.-M., Kuo, T.-W., Lin, Y., & Wu, H.-C. (2023) · Figshare · doi:10.6084/m9.figshare.23812506
Additional file 2 of Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Chiang, H.-L., Liang, K.-H., Lu, R.-M., Kuo, T.-W., Lin, Y., & Wu, H.-C. (2023) · Figshare · doi:10.6084/m9.figshare.23812509
Coordinated immune response distinguishes duration of SARS-CoV-2 viral particle shedding in humans
Schuster, D. J., Li, S. S., Mielke, D., Seaton, K., Brackett, C., Li, K., Shen, X., Wesley, M. S., Eisel, N., Yates, N. L., et al. (2026) · iScience · doi:10.1016/j.isci.2026.115277
Self-citation
Caractérisation de la réponse lymphocytaire B mémoire contre le SARS-CoV-2 après infection ou vaccination
Sokal, A. (2022) · theses.fr (ABES) · doi:10.70675/00bd0a63z263fz470az876czb50b49ba4313
Premières étapes dans l'interaction hôte-pathogène : rôle de l'immunité locale et innée
Michel, M. (2022) · theses.fr (ABES) · doi:10.70675/4647f4d2zd802z40abza572z8ff228db523f
Utilization of Similar Epitopes to Develop Viral Vaccines that Produce Lifelong Immunity
Yuan, S., Yang, X.-Y., Fu, Y.-F., Xie, L.-B., Zhang, Z.-W., Jiang, S.-C., Hu, J., Hu, J., Yuan, M., & Chen, Y.-E. (2026) · Viral Immunology · doi:10.1177/08828245261474283
“…surface accessible scores (Emini et al., 1985) > 2.0 was found in the receptor binding domain (RBD) region, which was also the N-terminus of the binding sequence to the human neutralizing monoclonal antibody CV30 (Hurlburt et al., 2020; Seydoux et al., 2020) and re-named here as epitope #A (Fig.”
Influential
Longitudinal BCR repertoire dynamics reveal the evolution of broadly binding antibodies following heterologous SARS-CoV-2 vaccination and breakthrough infection: a single-donor case study
Qiao, R., Chen, X., Zhang, X., Shao, Y., Zhang, L., Yang, L., Mi, Y., Lu, Y., Li, J., Chen, Y., et al. (2026) · Emerging Microbes & Infections · doi:10.1080/22221751.2026.2751804

Authors: Seydoux, E., Homad, L. J., MacCamy, A. J., Parks, K. R., Hurlburt, N. K., Jennewein, M. F., Akins, N. R., Stuart, A. B., Wan, Y.-H., Feng, J., Whaley, R. E., Singh, S., Boeckh, M., Cohen, K. W., McElrath, M. J., Englund, J. A., Chu, H. Y., Pancera, M., McGuire, A. T., & Stamatatos, L.
Affiliations: Fred Hutch Cancer Center (US)
University of Washington (US)
National Institutes of Health (US)
Corresponding author: Pancera, Marie
McGuire, Andrew T.
Stamatatos, Leonidas
ORCID: Seydoux, Emilie
Homad, Leah J.
MacCamy, Anna J.
Parks, K. Rachael
Hurlburt, Nicholas K.
Jennewein, Madeleine F.
Akins, Nicholas R.
Wan, Yu-Hsin
Feng, Junli
Whaley, Rachael E.
Singh, Suruchi
Boeckh, Michael
Cohen, Kristen W.
McElrath, M. Juliana
Englund, Janet A.
Chu, Helen Y.
Pancera, Marie
McGuire, Andrew T.
Stamatatos, Leonidas
Venue: Immunity
Publisher: Elsevier BV
Published: 2020-07
Volume: 53
Issue: 1
Pages: 98-105.e5
ISSN: 1074-7613 (ISSN-L)
DOI: 10.1016/j.immuni.2020.06.001
PMC: PMC7276322
OpenAlex: W3033450058
Cited by: 364
References: 44
Citations by year: 2026: 9 · 2025: 12 · 2024: 13 · 2023: 27 · 2022: 70 · 2021: 143 · 2020: 89
FWCI: 10.79
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 378 d)
Locations: Immunity (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Fred Hutchinson Cancer Research Center
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, spike protein, receptor binding domain, ACE2 receptor, somatic mutations, B-cell clonality, monoclonal antibodies, antibody epitope specificity, antibody affinity, antibody maturation, vaccine design
MeSH terms: Betacoronavirus, Angiotensin-Converting Enzyme 2, COVID-19, SARS-CoV-2, Antibodies, Monoclonal, Antibodies, Viral, B-Lymphocytes, Binding Sites, Humans, Peptidyl-Dipeptidase A, Pneumonia, Viral, Protein Binding, Receptors, Virus, Viral Vaccines, Coronavirus Infections, Epitopes, B-Lymphocyte, Somatic Hypermutation, Immunoglobulin, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks